NCT00787332终止4 期
A Comparative Clinical and Pharmacoeconomic Study Comparing Argatroban® IV vs Desirudin SC for Patients With Suspected Heparin-Induced Thrombocytopenia (HIT)With or Without Thrombosis Syndrome (HIT/TS)
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 入组人数
- 16
- 试验地点
- 24
- 主要终点
- New Thrombosis, Amputation, Death, Major and Minor Bleeding
研究概览
简要总结
Compare Clinical Success and Costs in two Arms
详细描述
Demonstrate clinical and economic utility between the study Arms.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provide written Informed Consent
- •Be at least 18 years of age.
- •A suspicion of heparin-induced thrombocytopenia with or without thrombosis syndrome (HIT/TS) due to one of the following clinical scenarios:
- •Patients who are receiving heparin/LMWH or have received heparin/LMWH within the previous 100 days AND one of the following:
- •have a fall in platelet count of > 30% from a baseline prior to heparin/LMWH, OR
- •have a thrombotic event, OR
- •develop skin lesions secondary to subcutaneous heparin (even if the patient is no longer receiving heparin therapy when thrombocytopenia, thrombosis or skin lesions occur).
- •Patients with thrombosis or skin lesions need not have concomitant thrombocytopenia to be included.
- •A rapid fall in the platelet count by >30% from baseline within 24 hours after starting heparin/LMWH in patients with suspected exposure to heparin or LMWH in the previous 100 days (e.g. hospitalization or invasive procedure within the past 100 days).
- •In post-operative cardiac surgery patients, development of thrombocytopenia defined as a decrease in platelet count by >30% from the post-operative peak; or patients whose platelet count fails to increase post-operatively (e.g. remains < 100,000 mm3 at Day 4 or later, calendar day of surgery=Day 0).
- •In patients with the diagnosis of HIT/TS established by a hematology consultant, but in whom the above criteria are not fulfilled, the Investigator should contact the Medical Monitor for consideration of the patient's inclusion in this study (A hematology consult is highly advisable, but not required prior to randomization).
排除标准
- •Confirmed pregnancy (if woman of child-bearing potential- urine or serum pregnancy test).
- •Patients with suspected or confirmed pulmonary embolism, requiring continued anticoagulation or acute ischemic stroke will be excluded
- •Cerebrovascular accident within the previous 6 months
- •Intracranial neoplasm, arteriovenous malformation or aneurysm.
- •Severe renal insufficiency as determined by measured or estimated creatinine clearance < 30 ml/min.
- •Known allergy to Argatroban®, Desirudin or hirudin derived drugs, or known sensitivity to any component of the product
- •Patients receiving recombinant hirudin (e.g. lepirudin) within the previous 6 months prior to enrollment.
- •Patients receiving >2 doses of fondaparinux for treatment of suspected HIT
- •Multi-system organ failure or estimated survival of less than 30 days.
- •Participation in other clinical research studies involving the evaluation of other investigational drugs or devices within 30 days of enrollment
- •Refusal to undergo blood transfusion should it become necessary
- •Active bleeding or irreversible coagulation abnormality
- •Uncontrolled hypertension defined as a blood pressure >180/110 mm Hg.
- •Patients requiring indwelling mechanical intervention such as left-ventricular assist device, intra-aortic balloon pump, veno-venous ultra filtration, etc.
- •Severe liver disease and any other disease or condition, which, in the judgment of the Investigator, would place a patient at undue risk by being enrolled in the trial, or cause inability to comply with the trial.
研究组 & 干预措施
Desirudin
Experimental
Patients with suspected HIT without thrombosis syndrome (HIT/TS), randomized to SC Desirudin
干预措施: Desirudin or Argatroban® (Drug)
Argatroban®
Active Comparator
Patients randomized to IV Argatroban®
干预措施: Desirudin or Argatroban® (Drug)
结局指标
主要结局
New Thrombosis, Amputation, Death, Major and Minor Bleeding
时间窗: 30 days
次要结局
未报告次要终点
研究者
研究点 (24)
Loading locations...
相似试验
已完成
4 期
Comparison Between Amoxycillin/Clavulanic Acid and Oxacillin/Ceftriaxone for Community Acquired-pneumoniaCommunity-Acquired PneumoniaNCT01166932UPECLIN HC FM Botucatu Unesp104
已完成
不适用
Clinical Performance and Cost Effectiveness of Biatain® Silicone Compared With Standard of CareVenous Leg UlcerDiabetic Foot UlcerNCT05786612Coloplast A/S102
已完成
不适用
Cost-effectiveness of two treatment strategies of an anterior cruciate ligament rupture. A randomized clinical study.ACL, anterior cruciate ligament , rupture, treatment options, VKB, Voorste kruisband ruptuur, behandelmogelijkheden,NL-OMON26654Prof. dr. J.A.N. Verhaar (Chair Department of Orthopaedics at Erasmus MC )166
已完成
不适用
Clinical and cost effectiveness of different emergency department healthcare professionals in soft tissue managementAcute peripheral musculoskeletal soft tissue injuryInjury, Occupational Diseases, PoisoningSoft tissue injuryISRCTN70891354niversity of the West of England (UK)900
尚未招募
不适用
‘Comparison of costs and patient reported outcomes of endovenous techniques in the treatment of incompetent saphenous veins;’A single center, double blinded, randomized controlled trial.varicose veins, endovenous treatment, VNUS, endolaserNL-OMON22362no sponsor70